Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide

Beata Kos-Kudła; Jarosław Ćwikła; Marek Ruchała; Alicja Hubalewska-Dydejczyk; Barbara Jarzab; Jolanta Krajewska; Grzegorz Kamiński

doi:10.5114/wo.2017.68619

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2017
vol. 21

Send email

Copy url:

abstract:

Review paper

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide

Beata Kos-Kudła

,

Jarosław Ćwikła

,

Marek Ruchała

,

Alicja Hubalewska-Dydejczyk

,

Barbara Jarzab

,

Jolanta Krajewska

,

Grzegorz Kamiński

Contemp Oncol (Pozn) 2017; 21 (2): 115–122

DOI: https://doi.org/10.5114/wo.2017.68619

Online publish date: 2017/06/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Kos-Kudła B, Ćwikła J, Ruchała M, et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemporary Oncology/Współczesna Onkologia. 2017;21(2):115-122. doi:10.5114/wo.2017.68619.

APA

Kos-Kudła, B., Ćwikła, J., Ruchała, M., Hubalewska-Dydejczyk, A., Jarzab, B.,  & Krajewska, J. et al. (2017). Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemporary Oncology/Współczesna Onkologia, 21(2), 115-122. https://doi.org/10.5114/wo.2017.68619

Chicago

Kos-Kudła, Beata, Jarosław Ćwikła, Marek Ruchała, Alicja Hubalewska-Dydejczyk, Barbara Jarzab, Jolanta Krajewska,  and Grzegorz Kamiński. 2017. "Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide". Contemporary Oncology/Współczesna Onkologia 21 (2): 115-122. doi:10.5114/wo.2017.68619.

Harvard

Kos-Kudła, B., Ćwikła, J., Ruchała, M., Hubalewska-Dydejczyk, A., Jarzab, B., Krajewska, J.,  and Kamiński, G. (2017). Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemporary Oncology/Współczesna Onkologia, 21(2), pp.115-122. https://doi.org/10.5114/wo.2017.68619

MLA

Kos-Kudła, Beata et al. "Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide." Contemporary Oncology/Współczesna Onkologia, vol. 21, no. 2, 2017, pp. 115-122. doi:10.5114/wo.2017.68619.

Vancouver

Kos-Kudła B, Ćwikła J, Ruchała M, Hubalewska-Dydejczyk A, Jarzab B, Krajewska J et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemporary Oncology/Współczesna Onkologia. 2017;21(2):115-122. doi:10.5114/wo.2017.68619.

PlumX metrics:

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a large and very diverse group of neoplasms. Clinical presentation of NETs depends on the site of the primary tumor and whether the tumor is functioning (i.e., secreting peptides or neuroamines that produce symptoms). The diagnosis of GEP-NET is further complicated by symptomatic differences that occur depending on the type of secreted peptide or neuroamine. Due to their heterogeneity and unique characteristics, early diagnosis of GEP-NETs is difficult, which increases the likelihood of metastatic disease and reduces the scope of therapeutic possibilities. Thus, a multidisciplinary approach for the treatment of GEP-NETs is necessary. This review is the result of presentations that were delivered during an expert meeting on the treatment of GEP-NETs supported by Ipsen. We summarize the current knowledge on the epidemiology, incidence, diagnosis, and treatment of GEP-NETs. We examined the role of the somatostatin analog (SSA) lanreotide and the impact of the data from the recently published, randomized, double-blind, placebo-controlled CLARINET study (Controlled study of Lanreotide Antiproliferative Response In Neuroendocrine Tumors) on disease management. We also review the recent treatment options and recommendations for GEP-NETs.

keywords:

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide

Beata Kos-Kudła , Jarosław Ćwikła , Marek Ruchała , Alicja Hubalewska-Dydejczyk , Barbara Jarzab , Jolanta Krajewska , Grzegorz Kamiński

gastroenteropancreatic neuroendocrine tumors, GEP-NETs, somatostatin analogue, lanreotide, CLARINET

Beata Kos-Kudła

,

Jarosław Ćwikła

,

Marek Ruchała

,

Alicja Hubalewska-Dydejczyk

,

Barbara Jarzab

,

Jolanta Krajewska

,

Grzegorz Kamiński